AngioLab (XKRX:251280) Debt-to-Asset : 0.04 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is AngioLab Debt-to-Asset?

AngioLab's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩58 Mil. AngioLab's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩26 Mil. AngioLab's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₩2,280 Mil. AngioLab's debt to asset for the quarter that ended in Dec. 2024 was 0.04.

AngioLab Debt-to-Asset Historical Data

The historical data trend for AngioLab's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Debt-to-Asset Chart

AngioLab Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.01

0.02

0.03

0.04

AngioLab Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Debt-to-Asset	Get a 7-Day Free Trial			0.03	0.01	0.02	0.03	0.04

Competitive Comparison of AngioLab's Debt-to-Asset

For the Biotechnology subindustry, AngioLab's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AngioLab's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AngioLab's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where AngioLab's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

AngioLab Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

AngioLab's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(58.049	+	26.165)	/	2279.662
	=	0.04

AngioLab's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(58.049	+	26.165)	/	2279.662
	=	0.04

AngioLab (XKRX:251280) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

AngioLab Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of AngioLab's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN

Website

http://www.angiolab.co.kr

AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab Headlines

No Headlines